Clinical Trials Logo
  1. Home
  2. Dyskinesia, Medication-induced
  3. NCT00175955

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Dyskinesia, Medication-induced Clinical Trial

Official title:
An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) on Neuroleptic-induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder, Aged From at Least 18 Years to 80 Years.

Clinical Trial Summary

An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00175955
Study type Interventional
Source UCB Pharma
Contact
Status Completed
Phase Phase 2
Start date May 2005
Completion date December 2005
View Details
See also
  Status Clinical Trial Phase
Completed NCT02657681 - Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS) Phase 2
Recruiting NCT05297201 - Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia Phase 2
Not yet recruiting NCT04147949 - AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia Phase 2